Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KELNOR 1/50 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Oral contraception
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: biphasic, terminal half-life 13-27 hours (mean ~17 h); norethindrone: monoexponential, half-life 5-14 hours (mean ~8 h). Steady-state achieved after 3-5 days. Accumulation may occur in patients with hepatic impairment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic via CYP3A4 (ethinyl estradiol) and various reductases (norethindrone acetate); undergoes extensive first-pass metabolism.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50% (as metabolites, primarily ethinyl estradiol glucuronide and sulfate conjugates; norethindrone metabolites). Fecal: ~35% (biliary excretion of conjugates followed by hydrolysis and elimination). Unchanged drug: <5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: ~97% bound to albumin (specific binding to SHBG). Norethindrone: ~92% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2-4 L/kg (distributes widely into body tissues, including breast, liver, adipose, and reproductive organs). Norethindrone: 3-5 L/kg (extensive distribution).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinyl estradiol ~40-45% (due to first-pass metabolism in gut wall and liver); norethindrone ~50-60% (presystemic metabolism).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, use is generally not recommended due to potential fluid retention and hyperkalemia; consider alternative contraception.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease or decompensated cirrhosis (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), no dose adjustment; use with caution and monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use in pediatric patients before menarche. For adolescent females post-menarche, same dosing as adults: one tablet orally daily per 21-day cycle.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific geriatric dose adjustments; evaluate cardiovascular and thromboembolic risks prior to use in women over age 35 who smoke or have risk factors.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking severity (particularly in women >35 years). Women who use COCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders (DVT, PE, stroke, MI),Vascular disease in diabetes mellitus,Hypertension,Gallbladder disease,Hepatic neoplasia,Carbohydrate/lipid effects,Ocular lesions (retinal thrombosis),Bleeding irregularities,Depression,Use in women with hereditary angioedema
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected carcinoma of the breast or endometrium,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Jaundice or hepatocellular disease with cholestasis (current or history),Heavy smoking (≥15 cigarettes/day) in women >35 years,Hepatic adenoma or carcinoma,Known or suspected estrogen-dependent neoplasia
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Grapefruit juice may modestly increase ethinyl estradiol levels but not clinically significant. St. John's Wort and some herbal supplements may reduce efficacy; avoid concurrent use. Maintain consistent diet if taken with food to avoid gastrointestinal upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Use is associated with cardiovascular defects, limb reduction defects, and neural tube defects. Second and third trimesters: Risk of feminization of male fetus, urogenital anomalies, and other congenital anomalies. Postnatal effects include behavioral and intellectual developmental issues.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Norethindrone (progestin) and mestranol (estrogen) are excreted into breast milk. M/P ratio for norethindrone is approximately 0.5–0.6. Mestranol is metabolized to ethinyl estradiol, with limited data on excretion. Breastfeeding is generally not recommended during use; may reduce milk production and quality. Avoid use in breastfeeding women due to potential adverse effects on infant.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustment guidelines exist because use is not recommended. If inadvertent exposure occurs, discontinue drug immediately; no pharmacokinetic-based dose adjustments are applicable.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
KELNOR 1/50 is a combination oral contraceptive containing ethinyl estradiol 50 mcg and norethindrone 1 mg. It has a higher estrogen dose than modern low-dose pills, increasing thrombotic risk. Use with caution in smokers over 35, hypertensive patients, and those with migraines with aura. Consider alternative contraception in women with BMI > 30 due to possible efficacy reduction. Monitor for breakthrough bleeding and ensure no missed doses to maintain contraceptive efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day, even if no intercourse occurs.,If you miss a pill, follow the package instructions; use backup contraception if needed.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Report any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or sudden severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding in the first few months.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KELNOR 1/50 vs AFIRMELLE, answered by our medical review team.
KELNOR 1/50 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KELNOR 1/50 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KELNOR 1/50 is: One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KELNOR 1/50 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KELNOR 1/50 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Use is associated with cardiovascular defects, limb reduction defects, and neural. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.